Safety and Efficacy of Exclusive Enteral Nutrition for Percutaneously Undrainable Abdominal Abscesses in Crohn’s Disease

Table 1

Demographic and clinical characteristics of CD patients with percutaneously undrainable abscesses by the treatment group.

Characteristics	EEN group ()	Non-EEN group ()
Gender, n (male/female)	32/22	15/14	0.509
Age at onset of abscess (y), median (range)	32.8 (17–51)	37.1 (17–60)	0.094
Disease duration (y), median (range)	4.3 (0.16–30)	5.5 (0.1–20)	0.274
Previous abdominal surgery, n (%)	11 (20.4)	8 (27.6)	0.456
Montreal classification of age, n (%)			0.526
A1 (<16 years)	0 (0)	0 (0)
A2 (17–40 years)	39 (72.2)	19 (65.5)
A3 (>40 years)	15 (27.8)	10 (34.5)
Montreal classification of disease location, n (%)			1.000
L1 (ileal)	18 (33.3)	10 (34.5)
L2 (colonic)	2 (3.7)	1 (3.4)
L3 (ileocolonic)	34 (63.0)	18 (62.1)
Abscess location, n (%)			0.574
Right lower quadrant	24 (44.4)	13 (44.8)
Pelvis	18 (33.3)	7 (24.1)
Others	12 (22.2)	9 (31.0)
Multiple abscesses, n (%)	8 (14.8)	7 (24.1)	0.293
Abscess diameter > 3 cm, n (%)	11 (11.1)	11 (24.1)	0.084
Fistula, n (%)	31 (57.4)	11 (37.9)	0.091
Perianal lesion, n (%)	7 (13.0)	7 (24.1)	0.227
Steroids at diagnosis, n (%)	18 (33.3)	14 (48.3)	0.182
AZA/6-MP at diagnosis, n (%)	20 (37.0)	14 (48.3)	0.321
Infliximab at diagnosis, n (%)	7 (13.0)	3 (10.3)	1.000
Laboratory indices
White blood cell (×10^9/L), mean, (range)	8.8 (3.6–15)	7.1 (2.7–11.6)	0.012
Hemoglobin (g/L), mean (range)	11.8 (6.1–15.8)	10.9 (6.6–14.1)	0.366
ESR (mm/h), mean (range)	36.7 (2–92)	33.3 (2–96)	0.574
C-reactive protein (mg/L), mean (range)	56.4 (3.9–202.4)	32.6 (0.4–159)	0.029
Albumin (g/L), mean (range)	32.5 (19.5–41.1)	30.8 (17–40.3)	0.216

ESR: erythrocyte sedimentation rate; EEN: exclusive enteral nutrition; AZA: azathioprine; 6-MP: mercaptopurine.